ESCRS - Supplement: Premium IOL Solutions - Your way out of the Labyrinth
Supplements

Supplement: Premium IOL Solutions - Your way out of the Labyrinth

Supplement: Premium IOL Solutions - Your way out of the Labyrinth

One-stop premium IOL provider

In today's premium intraocular lens (IOL) market, the abundance of lens options and surgical techniques is overwhelming, evoking a sense of navigating through a labyrinth. A new paradigm has emerged: the art of selecting the right lens to match each patient's unique visual needs and expectations.

Medicontur has become a one-stop premium IOL provider for leading clinics around the world. This supplement showcases Medicontur's premium lead technologies and clinical insights by leading experts in the field of refractive surgery, showing a way out of this labyrinth.

Latest Articles
Committing to a More Equitable Ophthalmology

Charity Committee enhances ESCRS’s reputation as a socially responsible society.

Read more...

Virtual Community Unites Ukrainian Eye Specialists

Microlearning platform proves vital to saving eyes and lives in areas of conflict.

Read more...

ESCRS Survey Shifts Industry Dial

Annual survey reveals trends and issues regarding the digital OR.

Read more...

Always Measure the Epithelium!

Epithelium thickness mapping key to better refractive outcomes.

Read more...

Brave New World of AI

More applications for anterior segment anticipated.

Read more...

Advancing Vision Research

National Eye Institute initiatives encourage AI-based innovations and data interoperability.

Read more...

Best Candidates for Phakic EDOF IOLs?

Patient profile suggests limits for phakic EDOF approach.

Read more...

Knowing Iris Repair: Iris Repair with Prosthetic Devices

New devices on the market expand available options when iris tissue is insufficient.

Read more...

Targeting the Kallikrein-Kinin System to Treat DME

Novel oral plasma kallikrein inhibitor shows promise in early clinical trial.

Read more...

Faricimab VOYAGER Study

Real-world experience with faricimab for treatment-naïve nAMD and DME is underway.

Read more...